(Fighting New Coronary Pneumonia) U.S. FDA Approves Emergency Use of Third New Coronary Vaccine
China News Agency, Houston, February 27. The US Food and Drug Administration (FDA) approved the emergency use license for the third new crown vaccine on the 27th.
The vaccine was developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The FDA said that the vaccine requires only one injection and can be stored in the refrigerator (2 to 8 degrees Celsius) for three months, which will help the United States speed up the safe vaccination rate.
Up to now, more than 510,000 people in the United States have died from the new coronavirus infection.
According to the Associated Press, the FDA said on the same day that the vaccine is approved for emergency use in adults 18 years and older, and it provides strong protection against moderate to severe new crown infections.
Johnson & Johnson Pharmaceuticals disclosed the test results in January showing that the vaccine named "JNJ-78436725" is about 66% effective in preventing moderate to severe new crown infections and about 85% in preventing severe new crown infections.
The FDA pointed out that there is no data to show how long the vaccine will last.
According to the Washington Post, the US government has signed a $1.5 billion contract with Johnson & Johnson to order 100 million doses of this new crown vaccine.
Johnson & Johnson recently stated to the US Congress that it is expected to provide the US government with 20 million doses of vaccine by the end of March this year and 100 million doses of vaccine by this summer.
It is estimated that shipments of 3 million to 4 million doses of vaccine will begin as early as March 1.
Due to logistics issues and severe weather, the US vaccination rate is currently slower than expected.
Data from the Centers for Disease Control and Prevention of the United States shows that as of February 27, the United States has distributed more than 96 million doses of vaccine, and approximately 48 million people have received at least one dose, of which nearly 24 million have completed two doses of the vaccine.
This is the third new coronavirus vaccine approved by the FDA for emergency use.
It is a recombinant adenovirus vector vaccine.
Previously, the FDA granted emergency use authorization to two vaccines jointly developed by the German Biotech Company and Pfizer Pharmaceuticals Co., Ltd. and developed by Modena in the United States.
They are both mRNA (messenger ribonucleic acid) vaccines and must be stored frozen.
Both vaccines adopt a two-dose vaccine program, and their effectiveness in preventing new crown infection is about 95%.
The Associated Press stated that since the time, scope, and procedures of phase 3 clinical trials of different new crown vaccines are different, their effectiveness in preventing new crown infections cannot be simply compared by numbers.
According to Reuters, Johnson & Johnson’s vaccine is expected to be widely used worldwide because it can be transported and stored at refrigerator temperatures.
The company plans to produce approximately 1 billion doses of vaccines globally by the end of this year.
Currently, the vaccine is being reviewed by the European Commission and the World Health Organization.
In addition, the South African government is also waiting for authorization from the health regulatory agency and hopes to seek more vaccines to combat the mutant new coronavirus B.1.351 discovered in South Africa.
Johnson & Johnson’s test results showed that the vaccine’s Phase 3 clinical trial in South Africa showed that it was 57% effective in preventing moderate to severe new crown infections.
(Finish)